Skip to main content

RegMedNet is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Our journals
    • Our journals
    • Journal content
    • Journal articles

    Follow us on social media

  • Topics
    • CAR-T
      • Stem cells
      • Cell therapy
      • Gene therapy
      • Gene editing
    • Cancer
      • Preclinical research
      • Tissue engineering
      • 3D printing
      • Biobanking
    • Clinical trials & funding
      • Manufacturing & scale-up
      • Regulation & policy
      • Industry developments

    Follow us on social media

  • Explore content
    • News
      • The week in cell therapy
      • Interviews
      • Opinion
      • Report
      • App Notes & White Papers
    • Spotlights
      • In Focus
      • eBooks
      • Webinars
      • Podcasts
      • Videos
      • Infographics
    • Find a partner
      • Events
      • Events coverage
      • The Glossary for Advanced Therapies

    Follow us on social media

  • Register
Spotlight exclusive: Expert insights on GMP media, xeno-free solutions and raw material management Read the interview!

iPSC expansion and differentiation: share your thoughts

29 Jul 2020
Written by RegMedNet
Cell therapy iPSCs Preclinical research

The latest Spotlight survey explores the use, challenges and future of induced pluripotent stem cells (iPSCs).

Share your expertise with the cell therapy community and let us know how you are utilizing iPSCs in the latest Spotlight survey.

Keep an eye out for the results of the survey, which will feature in our infographic later on in the Spotlight.

Take our short survey

For more content on iPSCs, visit out Spotlight homepage.

Top content

  • Cell therapy weekly: BLA submission planned for Huntington’s gene therapy AMT-130
  • eBook | Viral and non-viral gene delivery approaches
  • Building a consortium to accelerate stem cell models for drug discovery

Related tags

stem cell research
Previous article Next article

Related articles

3 JUL 2024 DISEASE AREA
A step closer to understanding Crohn’s disease
1 APR 2025 PRECLINICAL RESEARCH
Top 3 grants in regenerative medicine: March 2025
17 MAY 2024 STEM CELLS
First specific mechanism of stem-cell niche generation revealed
18 MAR 2021 NEWS
Not a dry eye in the house: stem cell-derived organoids produce tears in a dish
11 MAY 2021 NEWS
Gene therapy approach restores immune function to children with rare immunodeficiency disorder
28 OCT 2020 NEWS
Muscle stem cells could retain high regenerative capacity until geriatric age, study reveals
  • About
  • Advertising & Sponsorship
  • Expert Panel
  • Permissions & content ownership policy
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

RegMedNet is powered by Taylor & Francis Group

RegMedNet, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 RegMedNet